105(top 1%)
papers
4.6K(top 1%)
citations
25(top 1%)
h-index
68(top 1%)
g-index
106
all documents
4.8K
doc citations
1.1K
citing journals

Top Articles

#TitleJournalYearCitations
1European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood20131,743
2Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia2009808
3BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood2013187
4Vitamin D modulation of innate immune responses to respiratory viral infectionsReviews in Medical Virology2017176
5Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantationInternational Journal of Cancer2006153
6The Haemostatic Role of Tissue Factor Pathway InhibitorArteriosclerosis, Thrombosis, and Vascular Biology2008128
7The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemiaBlood2007126
8Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignanciesHaematologica2011114
9Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemiaBlood2009113
10Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapyLeukemia201097
11Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationAnnals of Oncology201389
12Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk PatientsBiology of Blood and Marrow Transplantation201182
13International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)Blood200880
14Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patientsBone Marrow Transplantation200362
15Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cellsBritish Journal of Pharmacology200956
16KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibLeukemia201248
17Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myelomaBlood201043
18The role of markers of bone remodeling in multiple myelomaBlood Reviews200541
19GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorderBritish Journal of Haematology200537
20Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolismBlood200336
21A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLBlood201735
22A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialBlood201234
23Initial treatment for patients with CMLHematology American Society of Hematology Education Program200929
24Design of optimal patient-specific chemotherapy protocols for the treatment of acute myeloid leukemia (AML)Computers and Chemical Engineering201327
25Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT.Blood200926
26Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working PartyLeukemia200725
27A Real-Time Multi-Channel Monitoring System for Stem Cell Culture ProcessIEEE Transactions on Biomedical Circuits and Systems200825
28EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation ProcedureBiology of Blood and Marrow Transplantation201225
29Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow TransplantationHaematologica201325
30Bisphosphonate treatment for multiple myelomaDrugs of Today200425
31Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow TransplantationBone Marrow Transplantation202124
32Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig ReceptorsJournal of Immunology200823
33Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitroExperimental Hematology200419
34Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemiaBritish Journal of Haematology200617
35Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial.Blood201017
36Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell TransplantationBiology of Blood and Marrow Transplantation201114
37MicroRNA-181a* Targets Nanog in a Subpopulation of CD34+ Cells Isolated From Peripheral BloodMolecular Therapy - Nucleic Acids201214
38A Short-activating RNA Oligonucleotide Targeting the Islet β-cell Transcriptional Factor MafA in CD34+ CellsMolecular Therapy - Nucleic Acids201313
39Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)Annals of Oncology201713
40Health-care professionals’ perspective on discussing sexual issues in adult patients after haematopoietic cell transplantationBone Marrow Transplantation201813
41Can we include vaccines with stem-cell transplantation?Nature Reviews Clinical Oncology200912
42Optimization of in vitro erythropoiesis from CD34+ cord blood cells using design of experiments (DOE)Biochemical Engineering Journal201112
43Ceramic Hollow Fibre Constructs for Continuous Perfusion and Cell Harvest from 3D Hematopoietic OrganoidsStem Cells International201811
44Simulation of ex vivo bone marrow culture: Application to chronic myeloid leukaemia growth modelBiochemical Engineering Journal201210
45Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.Blood200910
46First use of myeloid colony-stimulating factors in humansBone Marrow Transplantation20138
47Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence SurvivalBlood20087
48Nilotinib: evaluation and analysis of its role in chronic myeloid leukemiaFuture Oncology20116
49Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.Blood20106
50Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE TrialBlood20126